Ragaglitazar: The Pharmacokinetics, Pharmacodynamics, and Tolerability of a Novel Dual PPARα and γ Agonist in Healthy Subjects and Patients with Type 2 Diabetes-Reference-Cited by-同舟云学术

Ragaglitazar: The Pharmacokinetics, Pharmacodynamics, and Tolerability of a Novel Dual PPARα and γ Agonist in Healthy Subjects and Patients with Type 2 Diabetes

Published:2003-11 Issue:11 Volume:43 Page:1244-1256
ISSN:0091-2700
Container-title:The Journal of Clinical Pharmacology
language:en
Short-container-title:

Author:

Skrumsager B. K.,Nielsen K. K.,Müller M.,Pabst G.,Drake P. G.,Edsberg B.

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Reference34 articles.

1. Pathogenesis of type 2 diabetes mellitus;Dostou;Exp Clin Endocrinol Diabet,2001

2. PPARS, insulin resistance and type 2 diabetes;Kaplan;J Cardiovasc Risk,2001

3. Dyslipidaemia and diabetes;Betteridge;Pract Diabetes Int,2001

4. Pathogenesis of dyslipidemia in type 2 diabetes;Taskinen;Exp Clin Endocrinol Diabetes,2001

5. Peroxisome proliferator-activated receptor (PPAR) gamma agonists for diabetes;Moller;Adv Protein Chem,2001

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Phenoxyalkyl cyclic and acyclic amine derivatives: what do they teach us about scaffold-based drug design?;Medicinal Chemistry Research;2024-04-10

2. Assessment of mesalamine in the alterations of metabolic parameters in comorbid ulcerative colitis and metabolic syndrome patients: A retrospective study;2021-05-29

3. Multi-Target Drugs Against Metabolic Disorders;Endocrine, Metabolic & Immune Disorders - Drug Targets;2019-06-12

4. PPAR agonists, - Could tissue targeting pave the way?;Biochimie;2017-05

5. Tesaglitazar and other PPAR dual agonists;Meyler's Side Effects of Drugs;2016